Stereotaxis (STXS) AI Stock Analysis

• Market Cap: $174.08M
• Dividend Yield: N/A
• Average Volume (3M): 583.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.77
• Revenue Growth: 19.61%
• EPS Growth: -3.42%
• Country: US
• Employees: 139
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.06
• Shares Outstanding: 97,248,940
• 10 Day Avg. Volume: 380,338
• 30 Day Avg. Volume: 583,610
• PEG Ratio: 0.58
• Price to Book (P/B): 11.17
• Price to Sales (P/S): 6.46
• P/FCF Ratio: -15.18
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: 5.02
• Enterprise Value/Gross Profit: 9.53
• Enterprise Value/Ebitda: -8.17
• 1Y Price Target: $4.33
• Price Target Upside: 138.10% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.17
• Revenue Forecast (FY): $41.60M

• Rating: 47 Neutral
• Price Target: $2.00 ▲(9.89% Upside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is held back primarily by weak financial performance, with persistent losses and ongoing negative free cash flow. Technicals also reflect a sustained downtrend versus major moving averages. Offsetting factors include a more positive earnings-call outlook driven by GenesisX FDA approval and recurring-revenue momentum, while valuation remains difficult to assess due to negative earnings.

Positive Factors

Regulatory Milestone - GenesisX

FDA approval for GenesisX is a structural catalyst that removes a regulatory barrier to U.S. system placements. This expands the addressable market, supports more rapid system installations and recurring consumable sales, and underpins multi-year revenue growth and commercialization plans.

Recurring Revenue Growth

Rising recurring revenue—from disposables, catheters and service—reflects stronger utilization of the installed base. Predictable procedure-driven revenues increase revenue visibility, support margin stability given solid gross margins, and reduce reliance on lumpy one-time system sales over the medium term.

Manageable Leverage / Improved Equity

Lower leverage and higher equity in 2025 enhance financial flexibility to fund commercialization and R&D. With limited debt pressure, the company has more runway to support product launches and absorb losses, reducing near-term refinancing risk relative to a high-debt profile.

Negative Factors

Persistent Operating Losses

Stereotaxis has sustained large operating and net losses, with net margin deeply negative (~-67% in 2025). Persistent losses erode equity, hinder return metrics, and mean the company must demonstrate durable margin improvement to reach breakeven, or face material dilution or financing risk.

Negative Free Cash Flow / Cash Burn

Consistent negative operating and free cash flow indicates the business burns cash to fund growth and operations. Continued cash outflows increase dependency on external funding, which can dilute shareholders or restrict investments if capital markets tighten, impairing long-term execution.

Regulatory / Commercialization Dependency (MAGiC)

Key catheter approvals (MAGiC) remain pending in the U.S.; revenue and adoption forecasts rely on these regulatory outcomes. Delays or conditional approvals would slow adoption, reduce expected recurring revenue tail, and increase execution risk for the company’s product-led growth strategy.

Stereotaxis Business Overview & Revenue Model

Company Description

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

How the Company Makes Money

Stereotaxis makes money primarily by selling and supporting its robotic magnetic navigation ecosystem used in hospital electrophysiology labs. Key revenue streams typically include: (1) Capital equipment sales: one-time (or milestone-based) revenue from the sale and installation of its robotic navigation systems and associated hardware/software components to hospitals and medical centers. (2) Recurring revenue from disposables and consumables: revenue tied to procedure volume from the sale of single-use or limited-use items used with its systems, such as magnetically enabled catheter-related components and other procedure accessories (specific product mix and the extent of disposable revenue is company-dependent; if a particular disposable category is not disclosed, it is null). (3) Service, maintenance, and support contracts: recurring revenue from service agreements covering system maintenance, repairs, software support, and upgrades. (4) Software and upgrades: revenue from software modules, licenses, and/or system upgrades when offered separately from the initial system sale (if the company does not break this out publicly, it is null). The company’s earnings are influenced by the installed base of systems (driving service and procedure-related recurring revenue), adoption of robotic-assisted electrophysiology workflows by hospitals and physicians, and the pace of new system placements. Significant partnerships or distributor arrangements: null.

Stereotaxis Financial Statement Overview

Summary

Revenue growth has resumed and gross margin remains solid, with manageable leverage. However, persistent large operating losses and deeply negative net margins, alongside worsening negative free cash flow and ongoing cash burn, materially weaken overall financial quality and raise funding-risk concerns.

Income Statement

Revenue is growing again in the latest year (+7.7% in 2025 vs. essentially flat in 2024), but profitability remains very weak. Gross margin is still solid (~53% in 2025), yet operating losses are large and have persisted every year, with net margin deeply negative (about -67% in 2025). While net loss improved versus 2024, the business is still far from breakeven and shows meaningful volatility in revenue and margins over time.

Balance Sheet

Leverage looks manageable with low total debt and a reasonable debt-to-equity level (about 0.29 in 2025, improved from ~0.53 in 2024). Total assets are stable and equity increased in 2025 versus 2024, which helps financial flexibility. The key weakness is continued large losses driving very poor returns on equity (strongly negative), which can pressure the balance sheet over time if losses persist.

Cash Flow

Cash generation remains a major concern: operating cash flow and free cash flow are negative every year shown, including 2025 (operating cash flow about -$13.7M; free cash flow about -$13.8M). Free cash flow burn worsened in 2025 versus 2024 despite the reported growth rate, indicating higher cash usage. With ongoing cash burn alongside net losses, the company likely relies on external funding or balance-sheet resources to sustain operations.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	32.38M	26.92M	26.77M	28.15M	35.02M
Gross Profit	17.07M	14.59M	14.86M	18.47M	23.23M
EBITDA	-18.36M	-23.77M	-21.24M	-18.35M	-12.78M
Net Income	-21.64M	-24.05M	-20.71M	-18.29M	-10.72M
Balance Sheet
Total Assets	52.25M	46.72M	41.91M	53.41M	60.98M
Cash, Cash Equivalents and Short-Term Investments	13.42M	12.22M	19.82M	28.43M	38.74M
Total Debt	5.44M	6.01M	5.49M	5.86M	6.11M
Total Liabilities	33.53M	35.29M	19.99M	21.48M	21.56M
Stockholders Equity	18.72M	11.43M	21.92M	31.93M	39.42M
Cash Flow
Free Cash Flow	-13.78M	-8.53M	-9.51M	-10.79M	-4.34M
Operating Cash Flow	-13.69M	-8.50M	-9.14M	-8.41M	-2.95M
Investing Cash Flow	-93.00K	74.00K	19.77M	-22.09M	-1.40M
Financing Cash Flow	14.76M	297.00K	81.00K	220.00K	547.00K

Stereotaxis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STXS, the sentiment is Negative. The current price of 1.82 is below the 20-day moving average (MA) of 2.03, below the 50-day MA of 2.22, and below the 200-day MA of 2.48, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 31.51 is Neutral, neither overbought nor oversold. The STOCH value of 10.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STXS.

Stereotaxis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LMAT	78 Outperform	$2.42B	31.80	15.58%	0.95%	13.07%	27.98%
MMSI	68 Neutral	$3.96B	40.58	8.52%	―	11.49%	-2.89%
ATRC	60 Neutral	$1.45B	-165.01	-2.43%	―	15.80%	26.94%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STXS	47 Neutral	$174.08M	-9.67	-249.40%	―	19.61%	-3.42%
STAA	46 Neutral	$867.46M	-14.54	-23.24%	―	-32.42%	-540.37%
MLSS	42 Neutral	$19.37M	-8.10	-164.78%	―	0.59%	-39.76%